Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome

This study has been completed.

First Received on October 17, 2005. Last Updated on October 17, 2006 History of Changes

Sponsor:	St. Petersburg State Pavlov Medical University
Information provided by:	St. Petersburg State Pavlov Medical University
ClinicalTrials.gov Identifier:	NCT00241995

Purpose

The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome

Condition	Intervention
Topiramate Lamotrigine Memnatine Diazepam Placebo	Drug: Anticonvulsants

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment

Further study details as provided by St. Petersburg State Pavlov Medical University:

Eligibility

Ages Eligible for Study:	20 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Alcohol dependence Alcohol withdrawal syndrome

Exclusion Criteria:

Drug dependence Major psychiatric diagnoses Severe somatic illness

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241995

Sponsors and Collaborators

St. Petersburg State Pavlov Medical University

Investigators

Principal Investigator:

Evgeny M Krupitsky, MD, PhD

St. Petersburg State Pavlov Medical University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00241995 History of Changes
Other Study ID Numbers:	RCT-RCT_LOND_GAT_AWS_2003
Study First Received:	October 17, 2005
Last Updated:	October 17, 2006
Health Authority:	Russia: Ministry of Health and Social Development of the Russian Federation

Additional relevant MeSH terms:

Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012